Select Page

Press Release

DiaCarta’s Multivariant COVID-19 Test

Accurately Detects the Omicron Variant

Media Coverage by Genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay

to Gauge Chemotherapy Response

in Multiple Cancers

News Release

Former AstraZeneca Personalized

Healthcare Strategy Leader Named

Senior Vice President of

Companion Diagnostics at DiaCarta

News Release

DiaCarta’s Novel XNA Technology

Rapidly Detects Raging

New SARS-CoV-2 Variants

Publication in Nature Scientific Reports

DiaCarta Announces Publication in

Nature Scientific Reports

Demonstrating cfDNA Biomarker

Algorithm Predicts Response and

Outcome of Chemotherapy

Accurately Detects Orf1ab, N and E Genes with High Throughput

FDA Report:
Both of DiaCarta’s EUA authorized SARS-CoV-2 molecular diagnostic tests are listed in FDA website as among the top tier out of 117 in terms of sensitivity of the test with Limit of Detection (LoD) 600 NDU/mL or better.

Media Coverage by genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Press Release

DiaCarta Receives CE/IVD for its New COVID 19-Test that Identifies Delta Plus and New Variants

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers

News Release

Former AstraZeneca Personalized Healthcare Strategy Leader Named Senior Vice President of Companion Diagnostics at DiaCarta

News Release

DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants

Publication in Nature Scientific Reports

DiaCarta Announces Publication in Nature Scientific Reports Demonstrating cfDNA Biomarker Algorithm Predicts Response and Outcome of Chemotherapy

Accurately Detects Orf1ab, N and E Genes with High Throughput

FDA Report:
DiaCarta’s qRT-PCR COVID-19 Tests are at the Top Tier of All 117 EUA authorized SARS-CoV-2 Tests in Terms of Sensitivity of the Test

DiaCarta is a leading translational genomics and personalized diagnostics company based in Pleasanton, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.

HPV mRNA Screening

NGS Targeted Sequencing

CLIA Lab Service

ULTRA-SENSITIVE

XNA Technology

XNA, xenonucleic acids, are innovative new nucleic acid molecular oligomers that hybridize by Watson-Crick base pairing to target DNA sequences, and yet have a modified chemical backbone. XNA oligomers are highly effective at hybridizing to targeted normal DNA sequences and can be employed as molecular clamps in quantitative real-time polymerase chain reactions (qPCR) or as highly specific molecular probes for the detection of nucleic acid target sequences. The XNA tightly binds to the wild-type sequence that is 100% complementary and blocks DNA polymerase from DNA elongation; only the mutant target sequence gets amplified because the XNA:mutant DNA duplex is not stable due to mismatch and fall off from the template in PCR reactions.

ULTRA-SENSITIVE

SuperBDNA™ Technology

SuperbDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, SuperbDNA™ technology does not amplify the DNA or RNA in the samples, rather amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. SuperbDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases. 

Early Cancer Detection Will Save More Lives

linkedinfacebooktwitterCancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone....

Need Help?

Call us: +1 (800) 246-8878

Email us: information@diacarta.com

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X